EyePoint Pharmaceuticals

EyePoint Pharmaceuticals

Biotechnology Research

Watertown, MA 12,342 followers

Delivering Innovation to the Eye™ NOW HIRING!

Über uns

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Website
http://www.eyepointpharma.com
Industrie
Biotechnology Research
Größe des Unternehmens
51-200 Mitarbeiter
Hauptsitz
Watertown, MA
Typ
Öffentliches Unternehmen
Spezialitäten
Ophthalmology, Glaucoma, WetAMD, Optometry, Eye Disease, and Retinal Disease

Standorte

Employees at EyePoint Pharmaceuticals

Aktualisierungen

Verbundene Seiten

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

EyePoint Pharmaceuticals 10 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 215.9M

Siehe mehr Informationen auf crunchbase